Amna S. Al Balushi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Application of Machine Learning Models in Predicting Non-Alcoholic Fatty Liver Disease Among Inactive Chronic Hepatitis B Patients: A Cross-Sectional Analysis

    by Abdullah M. Al-Alawi, Amna S. Al-Balushi, Halima H. Al-Shuaili, Dalia A. Mahmood, Said A. Al-Busafi

    Background/Objectives: Non-alcoholic fatty liver disease (NAFLD) represents significant health challenges, especially among patients with chronic hepatitis B (CHB). This study uses machine learning models to predict NAFLD in patients with inactive CHB. It builds on previous research by employing classification algorithms to analyze demographic, clinical, and laboratory data to identify NAFLD predictors. Methods: A single-center cross-sectional study was conducted, including 450 inactive CHB patients from Sultan Qaboos University Hospital. Five ML models were developed: Logistic Regression, Random Forest, Extreme Gradient Boosting (XGBoost), Support Vector Machine (SVM), and Multi-Layer Perceptron (MLP). Results: The prevalence of NAFLD was 50.22%. Among the machine learning models, Random Forest achieved the highest performance with an ROC AUC of 0.983 (95% CI: 0.952–0.999), followed by XGBoost at 0.977 (95% CI: 0.938–0.999) and MLP at 0.963 (95% CI: 0.915–0.995). SVM also showed strong performance with an AUC of 0.949 (95% CI: 0.897–0.985), while Logistic Regression demonstrated comparatively lower discrimination with an AUC of 0.886 (95% CI: 0.799–0.952). Key predictive features identified included platelet count, low-density lipoprotein (LDL), hemoglobin, and alanine aminotransferase (ALT). Logistic Regression highlighted platelet count as the most significant negative predictor, while LDL and ALT were positive contributors. Conclusions: This study shows the utility of ML in improving the identification and management of NAFLD in CHB patients, enabling targeted interventions. Future research should expand on these findings, integrating genetic and lifestyle factors to enhance predictive accuracy across diverse populations.


  • Open Access

    Prevalence of Non-Alcoholic Fatty Liver Disease and Its Impact on Fibrosis Risk in Inactive Chronic Hepatitis B Patients: Insights from a Cross-Sectional Study

    by Said A. Al-Busafi, Amna S. Al Balushi, Halima H. Al Shuaili, Dalia A. Mahmood, Abdullah M. Al Alawi

    Background: Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are significant causes of chronic liver disease, potentially leading to liver cirrhosis and hepatocellular carcinoma. Moreover, the coexistence of CHB and NAFLD is increasingly common, although the relationship between NAFLD and inactive CHB infection remains poorly understood. Objectives: This study aimed to investigate the prevalence of NAFLD among patients with inactive CHB, identify risk factors for NAFLD, and determine predictors of significant fibrosis in these patients. Methods: This single-center cross-sectional study targeted patients with inactive CHB at Sultan Qaboos University Hospital from January 2010 to November 2021. Results: A total of 425 patients with inactive CHB were identified, of which 53.1% were male and 62.6% were aged 40–60 years. The prevalence of NAFLD was 47.8%. Various independent factors were associated with NAFLD, including type 2 diabetes mellitus, elevated low-density lipoprotein levels, high hemoglobin levels, low platelet counts, and normal alpha-fetoprotein levels. Significant associations were noted between NAFLD and significant fibrosis, with 10.5% of CHB patients with NAFLD exhibiting significant fibrosis compared to 1.4% of those without NAFLD. Other significant parameters included male gender, increased age, high alanine transaminase levels, elevated hemoglobin, and decreased platelet levels. Conclusions: The high prevalence of NAFLD in patients with inactive CHB and its associations with increased fibrosis and cirrhosis risk underscore the need for comprehensive management strategies for these patients.